Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA Testing Pilot Framework For Structured Benefit-Risk Assessment

Executive Summary

The Pharmaceutical Research and Manufacturers of America’s Benefit-Risk Action Team expects to complete pilot testing of a framework for conducting benefit-risk assessments by the end of 2011.
Advertisement

Related Content

Benefit-Risk Assessments For Me-Too Drugs Encouraged By FDA
FDA’s Benefit-Risk Framework Should Be Used Earlier In Development, Firms Say
FDA’s Structured Benefit-Risk Assessment Framework To Come Online In FY 2014
International Group Finds Harmony In Benefit-Risk Assessment Framework
FDA Pushes Back Against “Living” Benefit-Risk Assessment Management Plan
Benefit-Risk Assessment Framework Moves Toward Global Harmonization
Six Steps To Benefit-Risk Assessment
Six Steps To Benefit-Risk Assessment
PDUFA V Agreement Set In Four Areas, But Broad FDA/Industry Talks Continue
PDUFA V: Patients’ Opinions Could Get Formal Role In Review Decisions

Topics

Advertisement
UsernamePublicRestriction

Register

PS053765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel